Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioAge Labs, Inc. - Common Stock (NQ:BIOA)

7.040 -0.100 (-1.40%)
Streaming Delayed Price Updated: 10:06 AM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 68,099
Open 7.200
Bid (Size) 7.010 (400)
Ask (Size) 7.070 (100)
Prev. Close 7.140
Today's Range 6.970 - 7.260
52wk Range 5.040 - 25.95
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:BIOA),(NASDAQ:GERN),(NASDAQ:DNLI) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire

Performance

YTD
-45.1%
-45.1%
1 Month
-25.9%
-25.9%
3 Month
-71.3%
-71.3%
6 Month
-59.7%
-59.7%
1 Year
+29.2%
+29.2%

More News

Read More
News headline image
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
Top movers in Friday's session ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Gapping stocks in Friday's session ↗
Via Chartmill
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease ↗
Via MarketBeat
News headline image
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Via FinancialNewsMedia
News headline image
A Healthcare Fund Just Made Bitgo Its Biggest Bet ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials ↗
Via MarketBeat
News headline image
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Proposed Public Offering
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
From BioAge Labs, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is BioAge Labs, Inc. - Common Stock publicly traded?
Yes, BioAge Labs, Inc. - Common Stock is publicly traded.
What exchange does BioAge Labs, Inc. - Common Stock trade on?
BioAge Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioAge Labs, Inc. - Common Stock?
The ticker symbol for BioAge Labs, Inc. - Common Stock is BIOA on the Nasdaq Stock Market
What is the current price of BioAge Labs, Inc. - Common Stock?
The current price of BioAge Labs, Inc. - Common Stock is 7.040
When was BioAge Labs, Inc. - Common Stock last traded?
The last trade of BioAge Labs, Inc. - Common Stock was at 09/30/26 10:06 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.